PTO/SB/084 (08.03) Approved for use through 7/31/2006. OMB 0651-0031

10/531,347

February 27, 2006

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Application Number

Filing Date:

INFORMATION DISCLOSURE

(Form PTO-1449)				First Named Inventor		Jost SEIBLER et al				
		(Art Unit		1632		
						Examiner Nam	e;	Mar	cia Stephens Noble	
Sheet 1 of 2				Attorney Dock	et Number:	r: 100725-47 (KGB)				
				U.	S. PATE	NT DOCUM	IENTS			
Examiner's Cite Initials* No. 1			ent Number r-Kind Code ²	Publication Date MM-DD-YYYY		Name of Patentee or Applicant of Cited Docu			Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	AA	US -		_						_
	[AA	03-		FORE	EIGN PA	TENT DOC	LIMENTS	:		_
Examiner's	Cite No.	Foreign Patent Document Publicati			on Name of Patentee or Applicant of Cited Document			Pages, Columns, Lines, Where	T ⁶	
Initials*		Country Code ³ –Number ⁴ -Kind Code ⁵ MM-DD-Y		ument			Relevant Passages or Relevant Figures Appear	Relevant		
	AB	WO 03/057840 07-17-20		23 Allele Biotechnology & Pharmac		, &				
	AC									
			NON	PAT	ENT LI	ERATURE	DOCUMI	ENTS		
Examiner's Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.								
	AD	DEVROE E & SILVER P A; "retrovirus-delivered SiRNA"; BMC Technology, Biomed Central, London, August 28, 2002; pages 1-5 XP002225637								
	AE	BRUMMELKAMP T. R. et al: "Asystem for stable expressions of short interfering RNAs in mammalian cells"; American Association for the Advancement of Science, US; Vol. 296No. 5567 (2002), pages 550-553, XP002225638								
	AF	PAUL C. P et al: "Effective expression of small interfering RNA in human cells"; Nature Biotechnology, Nature Publishing US, Vol. 20, No. 5; May 2002, pages 505-508, XP001121006								
	AG	KISTNER et al.; "Doxycycline-mediated quantitative and tissue-specific control of gene expression in transgenic mice", Proceedings of the National Academy of Sciences of USA, Vol. 93, No. 20, October 1906, Pages 10933-10938, POOL 10022								
	AH	BRONSON, SARA K. et al; "Single-copy transgenic mice with chosen-site integration"; Proceedings of the National Academy of Sciences of the United States; Vol. 93, No. 19; (1996), pages 9067-9072, XP002270939								
	AI	HASUWA H. et al.: "Small interfering RNA and gene silencing in transgenic mice and rats"; Febs Letters, Elseviere Science Publishers, Amsterdam, NL; Vol. 532, No. 1-2; December 4, 2002, pages 227-230, XP04039375								
EXAMINER SIGNATURE:					DATE CONSIDERED:					
copy of this form	with next o	communicatio	on to applicant. 2App	plicant's un	nique citation	lesignation number (e	ptional). 2sec K	inds Code	if not in conformance and not considered. In s of USPTO Patent Documents at www.uspscents, the indication of the year of the reign of	gev

Emperor must precede the serial number of the patent document. 'Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached. The collection of information is required by 37 CFR 1.197 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting

the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08A (08-03)
Approved for use through 7/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB centrel number.

INFORMATION DISCUSSIBE

Application Number 10/531,347

		T BY APPLICANT'S	Filing Date:	Filing Date: February 27, 2006			
SIATE		(Form PTO-1449)	First Named Inventor	Jost SEIBLER et al			
		(Art Unit	1632			
			Examiner Name:	Marcia Stephens Noble			
Sheet 2		of 2	Attorney Docket Number:	100725-47 (KGB)			
		NON PATENT LITER	RATURE DOCUMENTS C	CONTINUED			
Examiner's Initials*							
	AJ		RNA1-mediated gene silencin rd University Press, Surrey, G	re controlled by tRNA Val g in the cytoplasm of human cells"; B; Vol. 31, No. 2, January 2003;			

AK	MATSUKURA, SHIRO et al; "Establishment of conditional vectors for hairpin siRNA knockdowns"; Nulccie Acids Research, England, August 1, 2003; Vol. 31, No. 15, pages 1-5, XP00227094.	
AL	VAN DE WETERING, MARC et al: "Specific inhibition of gene expression using a stably integrated, inducible small-inteerfering-RNA vector.", Embo Reports; Vol. 4, No. 6, June 2003; pages 609-618, XP00227094.	
AM	MERLINO G T, et al: "Accurate in-vitro transcriptional initiation of the chick alpha-2 type 1 collagen gene: Journal of Biological Chemistry, Vol. 256, No. 21; 1981, pages 11251-11258, XP00227094.	

AN AO EXAMINER SIGNATURE:

DATE CONSIDERED:

*EXAMINER: Initial if reference considered, whether or not cluston is in conformance with MFEP 609. Draw his through cluston if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unages claimed neighboring reprinted in the property of the

The control of the formation is supported by To CFR, 1977 and 1.08. The information is required to Ordina or extain a bound by the public which is to fif for each by the LSETO to proceed an application. Confidentially is powered by SS USC 122 and 75 CFR, 144. This collection is entimated to take 2-bears to complete, butching pathering process and substituting the completed application form to the USPTO. Time will vary depending upon the individual case. May comments on the amount of time you coquite to complete this form and/or suggestions for reducing the bentum, both the sent to the Claff information Officer. US prizes and Transformation (Fig. 70, Dos 1484, Alexandris, VA 22313-145). DO NOT SEND FEES OR COMPLETED FORMST OTHIS ADDRESS. SEND TO Commissioner for Patents, P.O. Box 1489, Alexandris, VA 22313-1450. DO NOT SEND IN Commissioner for Patents, P.O. Box 1489, Alexandris, VA 22313-1450. DO NOT SEND IN Commissioner for Patents, P.O. Box 1489, Alexandris, VA 22313-1450. DO NOT SEND IN Commissioner for Patents, P.O. Box 1489, Alexandris, VA 22313-1450. DO NOT SEND IN Commissioner for Patents, P.O. Box 1489, Alexandris, VA 22313-1450. DO NOT SEND IN Commissioner for Patents, P.O. Box 1489, Alexandris, VA 22313-1450. DO NOT SEND IN COMMISSIONER (Commissioner for Patents, P.O. Box 1489, Alexandris, VA 22313-1450. DO NOT SEND IN COMMISSIONER (Commissioner for Patents, P.O. Box 1489, Alexandris, VA 22313-1450. DO NOT SEND IN COMMISSIONER (Commissioner for Patents, P.O. Box 1489, Alexandris, VA 22313-1450. DO NOT SEND IN COMMISSIONER (Commissioner for Patents, P.O. Box 1489, Alexandris, VA 22313-1450. DO NOT SEND IN COMMISSIONER (Commissioner for Patents, P.O. Box 1489, Alexandris, VA 22313-1450. DO NOT SEND IN COMMISSIONER (Commissioner for Patents, P.O. Box 1480, Alexandris, VA 22313-1450. DO NOT SEND IN COMMISSIONER (Commissioner for Patents, P.O. Box 1480, Alexandris, VA 22313-1450. DO NOT SEND IN COMMISSIONER (Commissioner for Patents, P.O. Box 1480, Alexandris, VA 22313-1450. DO NOT SEND IN COMMISSIONER (Com